KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Receivables - Accured (2023 - 2025)

Twist Bioscience (TWST) has disclosed Receivables - Accured for 3 consecutive years, with $800000.0 as the latest value for Q4 2025.

  • Quarterly Receivables - Accured fell 42.86% to $800000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $800000.0 through Dec 2025, down 42.86% year-over-year, with the annual reading at $1.2 million for FY2025, 20.0% up from the prior year.
  • Receivables - Accured for Q4 2025 was $800000.0 at Twist Bioscience, down from $1.2 million in the prior quarter.
  • The five-year high for Receivables - Accured was $1.4 million in Q4 2024, with the low at $800000.0 in Q4 2025.
  • Average Receivables - Accured over 3 years is $1.1 million, with a median of $1.2 million recorded in 2023.
  • Peak annual rise in Receivables - Accured hit 20.0% in 2025, while the deepest fall reached 42.86% in 2025.
  • Over 3 years, Receivables - Accured stood at $1.2 million in 2023, then grew by 16.67% to $1.4 million in 2024, then tumbled by 42.86% to $800000.0 in 2025.
  • According to Business Quant data, Receivables - Accured over the past three periods came in at $800000.0, $1.2 million, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.